Drug intelligence / Profile preview

TAO1

Development stage: Phase 2
Lead developer: Theranor
Modality: Antibody-Based Therapeutics
Administration: Sublingual

Overview

TAO1, marketed as **Contaflu**, is an investigational sublingual homeopathic preparation consisting of high dilutions of rabbit-derived antibodies raised against a synthetic peptide from the cytoplasmic region of human Toll-like receptor 3. It was studied for early self-treatment of viral upper respiratory tract infections and common cold in the randomized ESTUAR trial. The registered product was supplied as sublingual tablets and was described as a proposed TLR3 immune modulator. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01651715))

Brand names: Contaflu

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on TAO1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAO1.

Explore the full profile